The latter findings have led to an ongo-ing clinical trial in adults with recent-onset T1D, involving the use of verapamil, a known antihypertensive calcium channel blocker, in suppressing TXNIP levels and improving beta cell function (Ovalle et al. 2018). The gene discussed is TXNIP; the disease is type 1 diabetes mellitus.